Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Sector: Healthcare; Industry: Biotechnology

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2018-12-18 Dukes Iain D. Director Buy 12,000 $8.65 $103,796 No
2018-12-13 MCPEAK MERRILL A Director Buy 10,000 $9.63 $96,273 No
2018-12-06 Rothbaum Wayne P. Director Buy 1,221,053 $10.20 $12,454,056 No
2016-08-25 Hillsberg Sanford Director Sell 54,000 $8.95 $483,412 No
2016-08-22 Hillsberg Sanford Director Sell 54,000 $9.11 $491,740 No
2015-09-08 Hillsberg Sanford Director Sell 32,500 $6.99 $227,085 No
2015-08-03 Hillsberg Sanford Director Sell 32,500 $8.15 $264,875 No
2015-05-01 Ayer Capital Management, LP 10%-Owner Sell 2,780,682 $9.62 $26,752,385 No
2015-05-06 Hillsberg Sanford Director Sell 50,000 $10.00 $500,000 No
2014-11-06 BRISTOL INVESTMENT FUND LTD 10%-Owner Sell 100,000 $690000.00 $69,000,000,000 No
2013-11-05 MCPEAK MERRILL A/ Director Buy 50,000 $2.00 $100,000 Yes
2013-11-05 Singh Manish President & CEO Buy 125,000 $2.00 $250,000 Yes
2011-08-22 Schroeder Martin Director Buy 1,000,000 $0.00 $1,000 No
2011-07-21 MCPEAK MERRILL A/ Director Buy 10,000 $1.40 $14,000 No

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.

Insider Smart

CEDAR FAIR L.P. (FUN) - Another crash victim, Cedar Fair L.P. took a deep dive from $54 to $13, insiders were confidence and eagerly jumped in around $27. With insiders on your side, this would be an easy add and hold to get your cost under $20. Stock is about to breach $40 in the coming weeks.